Sunday, January 29, 2023
News
NEWS HOME
PRN INDIA
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
  SocialTwist Tell-a-Friend  
   

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency

The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency

LEIDEN, Netherlands, Dec. 7, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that the positive results of a Phase 3 clinical trial of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, have been published in Blood,1 the peer-reviewed international medical journal of the American Society of Hematology. Data from this study was previously announced on February 2, 2022.

Pharming Group NV Logo

The paper, entitled 'Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome', outlined results from the multinational, triple-blind, placebo-controlled, randomized clinical trial, which enrolled 31 patients with APDS aged 12 years or older. Patients were randomly assigned in a 2:1 ratio to receive 70 mg leniolisib or placebo twice daily for 12 weeks. Improvement over placebo was significant in the co-primary endpoints which evaluated reduction in lymph node size and increase in naïve B cells, reflecting the impact on immune dysregulation and correction of immunodeficiency in these patients, respectively. The adjusted mean change (95% CI) between leniolisib and placebo for lymph node size was -0.25 (-0.38, -0.12; P=0.0006; N=26) and for percentage of naïve B cells was 37.30 (24.06, 50.54; P=0.0002; N=13). Leniolisib was well tolerated, and fewer patients receiving leniolisib reported study treatment-related adverse events (mostly grades 1-2) compared to those receiving placebo (23.8% vs 30.0%).

Vicki Modell, co-founder of the Jeffrey Modell Foundation, an international, non-profit, organization dedicated to helping individuals and family members affected by primary immunodeficiency disorders, commented:

"Pharming continues to provide significant support for the immunodeficiency community. The Jeffrey Modell Foundation is dedicated to early diagnosis and finding meaningful treatments for primary immunodeficiency, and we are acutely aware of the challenges faced by people with APDS. The publication of study results in this patient population in such a distinguished and widely read journal advances these goals."

Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:

"As we continue to seek a better understanding of APDS as a recently characterized rare disease, we remain committed to sharing our findings with researchers and doctors around the world. With this commitment in mind, we are pleased the results of this Phase III clinical trial in leniolisib have been published in the flagship journal of the American Society of Hematology.

The APDS patient population, and their families, have lived with unmet needs and without targeted therapies, and the publishing of this study is an integral step in improving the patient journey for this community. We are proud to share these results which demonstrated leniolisib to be a well-tolerated, targeted therapy for APDS. We thank all of our study participants and investigators for their efforts and the essential role they played in the development of leniolisib."

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)

APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway.2,3 Balanced signaling in the PI3Kδ pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.2,4 APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.5,6 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.7 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.5-8 The only way to definitively diagnose this condition is through genetic testing.

About Leniolisib

Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3Kδ is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3). Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Unlike PI3Kα and PI3Kβ, which are ubiquitously expressed, PI3Kẟ and PI3Kγ are expressed primarily in cells of hematopoietic origin. The central role of PI3Kẟ in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3Kẟ is a valid and potentially effective therapeutic target for immune diseases such as APDS. To date, leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ''anticipate'', ''believe'', ''could'', ''estimate'', ''expect'', ''goals'', ''intend'', ''may'', "milestones", ''objectives'', ''outlook'', ''plan'', ''probably'', ''project'', ''risks'', "schedule", ''seek'', ''should'', ''target'', ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any.

References

  1. Rao VK, et al. Blood. 2022. https://doi.org/10.1182/blood.2022018546.
  2. Lucas CL, et al. Nat Immunol. 2014;15:88-97.
  3. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
  4. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.
  5. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
  6. Maccari ME, et al. Front Immunol. 2018;9:543.
  7. Jamee M, et al. Clin Rev Allergy Immunol. 2019;May 21.
  8. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
Heather Robertson, Investor Relations & Corporate Communications Manager
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

US PR
Ethan Metelenis
E: Ethan.Metelenis@precisionvh.com
T: +1 (917) 882 9038

EU PR
Dan Caley
E: Dan.caley@aprilsix.com
T: +44 (0) 787 546 8942

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pharming-announces-publication-of-data-from-phase-3-study-of-leniolisib-in-patients-with-apds-in-ashs-blood-301696161.html

More News by PR Newswire India

Alexander Oelfke, CEO of SKYGROUND Group, announces the Group's new direction in an interview with BERLINER TAGESZEITUNG

IPM India Wholesale Trading Private Limited recognized as Top Employer for fourth Consecutive Year

Yonsei University Hosts the Global Engagement and Empowerment Forum (GEEF) 2023 to Tackle and Resolve Global Crisis

STL continues positive momentum towards global leadership and profitability

Optimum Nutrition launches campaign #thereismoreinallofus focussed on female athletes

CHEP accredited as a Top Employer in India

Godrej Agrovet launches Samadhan for farmers, becomes first Indian company to win IPOS certification

The NEW Shop ropes in Rajkummar Rao as brand ambassador: unveils expansion plans for 10000+ convenience stores by 2030

Woxsen University launches Project Aspiration to empower marginalised adolescent girls

Magic Software's Magic Pathsala Announces Partnership with Kapil Dev's Khushii

Mystore launches ONDC connector for Shopify sellers

PARCOS MEET & GREET WITH NORTHEAST UNITED FC TEAM

Government of Sharjah Honours Partners With NFT Plaque Using SBT Technology for their Support at GITEX Global 2022, becomes world's first to do so

Communicators Make Historic Strides in C-suite Impact

Encora Announces the Acquisition of Excellarate, Strengthening Its Capabilities in HealthTech, FinTech and InsurTech

KellyOCG earns recognition as a John Deere "Partner-level Supplier"

Kohler Co. Celebrates 150 Years of Bold Moves, Creativity, and Impact While Shaping the Next 150 Years of Its Iconic KOHLER Brand

JobzMall Unveils the World's Largest Video Talent Marketplace

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

THE ROYAL CANADIAN MINT ANNOUNCES NUMISMATIC COIN COLLECTION HONOURING THE LIFE AND REIGN OF QUEEN ELIZABETH II

Frost & Sullivan Awards Nexthink with the 2022 Company of the Year Award for Improving the Digital Employee Experience

Climate Connect Digital - Achieves carbon neutrality for Fiscal Year 2021-2022

Esaote presents the world premiere of its new MyLab™X90 ultrasound device

Going live again at last: Spielwarenmesse 2023 turns into a grand reunion with numerous highlights

Alma, a Sisram Medical company, announces the launch of Alma Duo - an advanced, FDA and CE approved solution that promotes sexual wellness for men and women

This Republic Day, Delve Into the Rich Indian Heritage and Pre-Independence Era Experiences at Noormahal Palace

Crave InfoTech launches SAP BTP-powered cMaintenance for Intelligent Asset Management

Official Global Release of the New Mobile Puzzle Game 'Pucca Puzzle Adventure' on January 26

MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study

Global Ride-Hailing Platform inDrive Partners SHIELD to Boost Trust and Fairness

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

SMMT : 2022 UK car production down but electric vehicle output surges to new record

Scrub Daddy Inc. to partner with Unilever on co-creating innovative cleaning products, partnership to appear on ABC's Shark Tank episode on 01/27/2023

Correction - Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Breg Partners with Correal International to Provide Orthopedic Products to Physicians & Patients in China

Doodles 2 Launching on Flow, as the Web3 Giant Begins its Journey to Onboard Millions

CO.DON finally saved - investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg.

Inaugural Event of the TEDxAllianceUniversity Themed 'Beyond Boundaries' was Graced by Inspirational Speakers Who Shared Life Lessons and Ideas Worth Platforming

ZingHR moves into a New Era in 2023 with "Outcomation" the new mantra for Tangible Business Outcomes for Enterprises

PlumCare RWE partners with Lifebit on Greece's newborn genomic sequencing program, BeginNGS

Information Services Group Report Recognizes Armis as a Leader in OT Security for the Third Year in a Row

Intex revolutionizing the market of technology for the next generation with an all-new campaign

Survey by FINFI finds a huge gap between the benefits that employees want and the benefits offered by the employers in India

Aon: Global Insured Losses from Natural Disasters Exceeded $130 Billion in 2022, Driven by Second-Costliest Event on Record

Tive Adds 250+ New Customers & Achieves 80% Year-Over-Year Growth in 2022

Olectra Greentech Limited Unaudited Standalone Q3 FY 22-23 Results

Shutterstock Introduces Generative AI to its All-In-One Creative Platform

Bank of Baroda establishes the 'Bank of Baroda Rashtrabhasha Samman'

Companies Fall Short on Climate Pledges by Failing to Embed Net-Zero Actions Into Operations, Survey Finds

Liberty General Insurance transforms customer experience of over 100,000 customers in CY 2022 through AI enabled Vehicle Inspections - a scalable, low cost & customer centric solution

Manipal Hospital Old Airport Road performs first of its kind plasma filtration for a pregnant woman

Infosys serves up purpose-driven digital innovations with sustainability off-court and AI on-court at the Australian Open 2023

Maple's Biggest Republic Day Sale: iPhone 13 price down to Rs. 59,999 and iPhone 14 at Rs. 67,900

SBM-NMIMS Mumbai Hosts the 8th Conference of Indian Academy of Management

XOR Labs Helps Ethnic Wear Brand Grow by 2.5x in Three Months

National Excellence Awards organized by Kiteskraft Productions

Universal Digital Payments Network (UDPN) is launched to support seamless digital payments across multiple central bank digital currencies and regulated stablecoins

PlatAfrica winners shine during PGI India visit

StockEdge launches India's first AI-powered screening mechanism to automatically identify Chart Patterns in different stocks with StockEdge Pro

Ithra presents new ways to experience and learn about KSA's cultural heritage at the Diriyah Islamic Arts Biennale

Andes Technology Collaborates with LDRA to Deliver Integrated Tool Suite for Safety-Critical Software on Andes RISC-V CPU Solutions

Contextual Advertising Expert Seedtag Enters Indian Market

FlowerAura Foresees Exponential Growth in Sales with its Newly Launched Valentine's Gifts 2023

Despite global slowdown, Asia's economies show resilience and growth for 2023 - according to Asia House's Annual Outlook

Web3 experience like never before: Polkadot Hub is opening in Bali

WDO launches call for proposals to host its World Design Assembly in 2025

Algorand Foundation Appoints Jessica Tsai Chin as Chief Marketing Officer

SEMICON West Makes Two Big Moves - Shifts to October in 2024, Begins Annual Rotation With Phoenix in 2025

CarTrade Tech reports its highest ever quarterly revenue at Rs. 115.86 crores and highest ever quarterly adjusted EBITDA at Rs. 36.60 crores for Q3 FY 23

Top Rated Global Workforce Management Solutions Provider WorkForce Software Welcomes Nicole Neumarker as Chief Technology Officer and Bill Razzino as Chief Financial Officer

UltiMaker Launches the S7 - The New Flagship S-Series 3D Printer

PKWARE Announces New Solution for Securing Sensitive Information within Microsoft Outlook Email

adidas Originals and Bollywood Superstar, Ranveer Singh team up to challenge conventions and hack the old codes of luxury in the latest Spring Summer' 23 campaign

Stamus Networks Appoints Vice President, Customer Solutions

Metabolon Secures $25 Million of Funding to Accelerate Growth

Ninety-two percent of organizations think they need to do more to reassure customers about how their data is used in AI, new Cisco research finds

Fortune Selects Abu Dhabi as Host City of the 2023 Fortune Global Forum

Press Statement: International Day of Education

Altair and TU Delft Sign Campuswide License Agreement

CIO CHOICE 2023 Recognizes Airtel Business - Lavelle Networks as the Most Trusted Brand in SD-WAN Platform

SPJIMR study highlights that family issues pose greater headwinds for small and medium Indian family enterprises than the uncertain and volatile business environment

Barcode Entertainment appoints Ajay Kulkarni as its Business Head

Prudent Corporate Advisory Services Limited AUM crosses noteworthy milestone of ₹55,000 crore in Q3FY23

Armis State of Cyberwarfare and Trends Report: 2022-2023 Highlights Global IT and Security Professionals' Sentiment on Cyberwarfare

Credence Security, leading regional VAD, rebrands as 'TRINEXIA' to Drive New Era for Innovation and Cyber Resilience

Hexaware Recognized by ICSI for Excellence in Corporate Governance

Tata AIA Life Insurance Sampoorna Raksha Supreme is now more powerful with Tata AIA Vitality Riders benefits

Aeroitalia Partners with WorldTicket to Expand Options for Travel in the European Region

UST and Leapwork Collaborate to Help Companies Reduce Risks During Digital Transformation

Alstom in India recognised as 'Top Employer' for the third consecutive year

Lighthouse Canton wins 'Best Independent Wealth Manager - Asia Pacific' at Asian Private Banker Awards for Distinction 2022

Bakingo to Expand Capacity & Outreach, Eyeing Substantial Growth in 2023

Crave InfoTech launches white paper on SAP BTP as an intelligent platform

Grower-Owned Hop Supplier and New Zealand Grower Cooperative Enter Global Partnership

TON validators will vote on the suspension of inactive addresses holding a total of over 1bn Toncoin

Vectorworks and Solibri Inside Integration to Save Architects Time and Money

Philips Audio expands its Headphones category with the launch of TAH8506BK

KISS Organises Mega Guardians' Meet

Nanoprecise Applauded by Frost & Sullivan for Preventing Sudden Industrial Equipment Downtime and Related Losses with Its Predictive Maintenance Solution

AG&P PRATHAM LAUNCHES TWO LIQUIFIED AND COMPRESSED NATURAL GAS (LCNG) STATIONS IN KERALA

Frost & Sullivan Recognizes Future-Ready Companies at the India Manufacturing Excellence Awards 2022

CAMLIN FINE SCIENCES LAUNCHES ADORR™ VANILLIN, MANUFACTURES IN INDIA

K-DISC Headquarters setting new example in Energy Conservation

NADA Joins MOBI to Accelerate Zero Trust Innovations for Information Security and Business Automation

Delivering On Our Promise of Universal Education - Education Cannot Wait

Dr. Sujata Seshadrinathan receives Women's Entrepreneur of the Year award for the SAARC region

PreIPO to participate in $250M fundraising round for SPiCE II as SPiCE I named Top VC fund of 2022 in Blockchain Ecosystem

RT-RK integrates mARTini Android container solution on Telechips Dolphin 3

Icelandic ON Power Scales up EV Charging Service Offering with Landis+Gyr Charge Point Management System

The Keyrus Group enters the final phase of making a strategic investment in Sonum International - a European EPM leading player and a specialist in Anaplan®.

ANMI StockTech Survey Reveals Industry Shift towards Tech-Driven Brokerage

ACCEPTANCE PERIOD FOR EXCHANGE OFFER EXTENDED PENDING COMPETITION CLEARANCES

MELANIE GRANT APPOINTED AS NEW EXECUTIVE DIRECTOR OF THE RESPONSIBLE JEWELLERY COUNCIL

Purple Quarter Facilitates the VP of Data Science for WayCool's Tech Arm CENSA

Bakingo Talks about New Launches and Exponential Growth for Valentine's Day 2023

EDS Technologies launches Business Consulting Division for Digital Transformation

OCP Group and India enter a strategic partnership to strengthen food security and confirm their common ambition for an innovative and sustainable agriculture

ReSight Global acquires PeepalDesign, leading UX firm in India

Chinese New Year's greetings from China's Guangdong

INX ANNOUNCES THE LAUNCH OF NEW BOOK, THE INX WAY

ROYAL CANADIAN MINT WINS TWO COIN OF THE YEAR AWARDS, CAPTURING "BEST CROWN" AND "BEST CIRCULATION" COIN CATEGORIES

GameChange Solar Awarded Group of Projects Totaling 2.3 GW for Genius Trackers™ in Florida, USA

Collabera, LLC Welcomes Mike Fromhold as New Chief Executive Officer

Public Interest Registry Launches .GIVING, New Top-Level Domain to Streamline Online Fundraising

BIOMERICS COMPLETES CONNECTICUT EXPANSION

Pixalate Announces December 2022 Top Programmatic Sellers (SSPs) By Market Share For Mobile Advertising Across Google And Apple Platforms

eQ Technologic Joins AWS Partner Network

Global Review 2022: GWM Expands Its Global Layout, Empowered by Forest Ecosystem

Masdar to Develop 5 GW of Renewable Energy Projects to Advance Africa's Clean Energy Objectives

Course5 Intelligence is Great Place To Work® Certified™ Again

Rogers International Commodity Index (RICI®): Weights unchanged but Random Length Lumber Futures contract (CME:LBS) will transition to Lumber Futures contract (CME:LBR) effective with January 2023 roll period

Dangerously unrealistic house rental market has effected the Interstate removalists Sydney, according to City Removalist

Plastindia 2023, Discover 13 French companies under the 'French Fab' excellence brand showcasing innovative solutions and equipment for the plastic industry

OPEC Fund mobilizes US$1 billion for development finance with landmark debut SDG bond

Patent granted for OCUSERT - a breakthrough Glaucoma treatment developed by the team at NMIMS SPPSPTM

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Ankita Bhandari murder case: Polygraph-n...
Woman arrested for creating ruckus outsi...
Both Houses not to have Zero Hour, Quest...
Despite repeated warnings students scree...
J-K: Pulwama ADGP dismisses allegations ...
MP CM announces to give Rs 1,000 a month...
More...    
 
 Top Stories
Mithali Raj appointed mentor and ad... 
Kanye West throws pap's phone in th... 
Australian Open: Sabalenka holds of... 
Int'l conference of liver specialis... 
Woman arrested for creating ruckus ... 
ISL: ATK Mohun Bagan moves to third... 
Link found between multiple scleros... 
Both Houses not to have Zero Hour, ...